| Name | Title | Contact Details |
|---|
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have built our business model consistent with this belief, and through it, we are impacting people around the world with each passing year. Providing universal access to medicine is the core purpose of our model. To provide access, we must be able to satisfy the needs of an incredibly diversified global marketplace whose economic and political systems, approaches to delivering and paying for healthcare, languages and traditions, and customer and patient requirements vary by location and over time.
At Precision for Medicine, we help our pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products. Backed by a diverse team of experts across the spectrum of the healthcare marketplace, we provide a comprehensive and integrated set of services that help accelerate research, enable market adoption, enhance patient outcomes, and realize the full commercial potential of new therapies and products.
RotaChrom Technologies is the inventor and first worldwide manufacturer of the Industrial Scale Centrifugal Partition Chromatography (iCPC) platforms. The company revolutionizes the pharmaceutical and cannabis industries by manufacturing and selling unique inventions of a special purifying technology. A cost-efficient and easily adaptable separation solution is offered for active pharmaceutical ingredients (API) and cannabinoids. The cost and the risk profile of R&D, as well as production can be significantly lower by using CPC tools, thereby pharmaceutical and cannabis-based products can become more widely available. Since its establishment, the company has achieved massive international success in pharmaceutical and pharma-graded cannabis purification. It has become an industry-leading company by setting global purification standards in the cannabis industry. RotaChrom’s CPC platforms are quintessential applications when looking for a high-purity and high-capacity, yield-focused solution.
Cadila Pharmaceuticals - CPL, Inc. is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.